# EDGAR Filing Document

**Accession Number:** 0001759655
**File Stem:** 0001759655-25-000080
**Filing Date:** 2025-7
**Character Count:** 11464
**Document Hash:** e288fc4d2de0d1c0f34e2cefa9d6ee66
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001759655-25-000080.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001759655-25-000080

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250703

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Privia Health Group, Inc.
- **CENTRAL INDEX KEY:** 0001759655
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40365
- **FILM NUMBER:** 251109635

**BUSINESS ADDRESS:**
- **STREET 1:** 950 N. GLEBE RD., SUITE 700
- **CITY:** ARLINGTON
- **STATE:** VA
- **ZIP:** 22203
- **BUSINESS PHONE:** 571-366-8850

**MAIL ADDRESS:**
- **STREET 1:** 950 N. GLEBE RD., SUITE 700
- **CITY:** ARLINGTON
- **STATE:** VA
- **ZIP:** 22203

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PH Group Parent Corp.
- **DATE OF NAME CHANGE:** 20181120

?xml version='1.0' encoding='ASCII'? prva-20250703

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**_________________________**

**FORM 8-K**

**_______________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 3, 2025**

**_________________________**

**Privia Health Group, Inc.** 

**(Exact Name of Registrant as Specified in Its Charter)**

**_________________________**

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **001-40365** | **81-3599420** |
| (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) | (Commission<br>File No.) | (I.R.S. Employer Identification No.) |
| **950 N. Glebe Rd.,** | **950 N. Glebe Rd.,** | | |
| **Suite 700** | **Suite 700** | | |
| **Arlington,** | **Virginia** | | **22203** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | | (Zip Code) |

---

**(571) 366-8850** 

Registrant's telephone number, including area code

**Not Applicable**

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock, $0.01 par value per share | PRVA | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The Board of Directors (the "Board") of Privia Health Group, Inc. (the "Company") increased the size of the Board from nine to ten directors and elected Lance Berberian to the Board as a Class III director, effective July 15, 2025. The Board also appointed Mr. Berberian as a member of the Audit Committee of the Board effective July 15, 2025.

The Board has determined Mr. Berberian to be independent in accordance with the independence standards of the rules of The Nasdaq Stock Market, and the heightened independence standards, financial sophistication and financial literacy requirements for Audit Committee service. There are no arrangements or understandings between Mr. Berberian and any other persons pursuant to which Mr. Berberian was selected as a director, and there are no transactions in which Mr. Berberian has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K.

As compensation for his service as a director, Mr. Berberian will receive an annual cash retainer in accordance with the terms and conditions of the Company's Non-Employee Director Compensation Program (the "Director Compensation Plan"). Consistent with the terms of the Director Compensation Plan, Mr. Berberian will also receive an annual equity grant, pursuant to the 2021 Omnibus Incentive Plan, as amended, of restricted stock units with a grant date fair market value of $200,000. Mr. Berberian will receive an initial grant pro-rated for the number of months that he will serve on the Board through the date of the next annual meeting of stockholders. The terms and conditions of these grants will be governed by an agreement substantially in the form of the Company's Form of 2021 Omnibus Plan Restricted Stock Unit Award for Non-Employee Directors.

On July 8, 2025, the Company issued a press release announcing the election of Mr. Berberian to the Board. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibit:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Privia Health Group, Inc. Press Release Dated Ju](ex-991prpriviahealthappoin.htm)[ly](ex-991prpriviahealthappoin.htm)[8](ex-991prpriviahealthappoin.htm)[, 2025](ex-991prpriviahealthappoin.htm)</u> |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | PRIVIA HEALTH GROUP, INC. | PRIVIA HEALTH GROUP, INC. |
| Date: July 8, 2025 | By: | /s/ Parth Mehrotra |
|  |  | Name: Parth Mehrotra |
|  |  | Title: Chief Executive Officer |

---

## Exhibit 99.1

---

| | |
|:---|:---|
| ![privialogo.jpg](privialogo.jpg) | **Exhibit 99.1** |
| ![privialogo.jpg](privialogo.jpg) | |
| ![privialogo.jpg](privialogo.jpg) | |
| ![privialogo.jpg](privialogo.jpg) | |

---

**Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors**

*Berberian brings significant technology leadership and cybersecurity expertise*

**ARLINGTON, VA – July 8, 2025** – Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors.

"We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as we continue to grow our business and build scaled provider networks across the U.S."

Mr. Berberian is a technology strategist with over 30 years of experience specializing in digital transformation and corporate governance. From 2014 to October 2024, he served as EVP and Chief Information and Technology Officer at Labcorp Holdings Inc. (NYSE: LH), overseeing a team of 5,000 people focused on IT strategy, cybersecurity, AI, product development, and data management. Prior to Labcorp, Mr. Berberian held CIO roles at IDEXX Laboratories, Kellstrom Aerospace, Interim HealthCare and Quest Diagnostics.

Mr. Berberian currently serves on the Elon University Board of Trustees and previously chaired the NC State Computer Science Strategic Advisory Board. He holds a bachelor's degree in business administration and information technology from Thomas Edison State College.

**About Privia Health**

Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 15 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,200+ physician practices, improve the patient experience for 5.2+ million patients, and reward 4,800+ physicians and advanced practitioners for delivering high-value care.

Privia's mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit <u>priviahealth.com</u> and connect with us on <u>LinkedIn</u>.

**Safe Harbor Statement**

This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company

------

---

| | |
|:---|:---|
| ![privialogo.jpg](privialogo.jpg) | **Exhibit 99.1** |
| ![privialogo.jpg](privialogo.jpg) | |
| ![privialogo.jpg](privialogo.jpg) | |
| ![privialogo.jpg](privialogo.jpg) | |

---

does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

**Contact:**

Robert Borchert

SVP, Investor & Corporate Communications

IR@priviahealth.com &nbsp;&nbsp;&nbsp;&nbsp;

817.783.4841 <br>